Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rhabdomyosarcoma
What role do genetic and molecular profiling play in predicting which patients with high-risk localized RMS benefit from maintenance chemotherapy with vinorelbine and low-dose cyclophosphamide?
Related Questions
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
What workup needs to be performed on pediatric patients with warm autoimmune hemolytic anemia prior to initiation of treatment with immunosuppressants?
When would you consider genetic testing for G6PD deficiency diagnosis?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
What is your diagnostic and treatment approach to pediatric patients with erythrocytosis?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
What is your experience with managing patients with STEAP3 mutation and non-transfusion related iron overload?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
